Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after getting confirmation it will be covered by the NHS in all four nations.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM – Research Report) and Reviva ...

At close: 21 January at 3:00:00 pm GMT-5 ...

Swiss biotech Santhera has found a North American partner ... Florida-based rare disease specialist Catalyst Pharmaceuticals is paying $90 million upfront for rights to vamorolone, across all ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Vanda Pharmaceuticals stock opened at $4.51 on Tuesday. The business’s 50-day simple moving average is $4.81 and its 200-day simple moving average is $5.03. The firm has a market capitalization ...

Royal Bank of Canada restated their sector perform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research note issued to investors on Tuesday,Benzinga reports.

Analyst Madison Elsaadi of B.Riley Financial reiterated a Buy rating on Eton Pharmaceuticals (ETON – Research Report), retaining the price target of $21.00. Madison Elsaadi has given his Buy ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that ...